Cel-Sci Total Long Term Liabilities 2010-2025 | CVM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cel-Sci total long term liabilities from 2010 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cel-Sci total long term liabilities from 2010 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$249.7B
Amgen (AMGN)	$159.6B
Gilead Sciences (GILD)	$147.3B
Vertex Pharmaceuticals (VRTX)	$101.1B
Bristol Myers Squibb (BMY)	$98.2B
GSK (GSK)	$81.6B
CSL (CSLLY)	$68.5B
Regeneron Pharmaceuticals (REGN)	$62.6B
Alnylam Pharmaceuticals (ALNY)	$60.1B
Argenex SE (ARGX)	$40.5B
Insmed (INSM)	$27.4B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$21.5B
Biogen (BIIB)	$20.4B
Incyte (INCY)	$16.8B
Genmab (GNMSF)	$15.9B
Illumina (ILMN)	$15.5B
Genmab (GMAB)	$15.4B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$10.9B
Moderna (MRNA)	$10.5B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Halozyme Therapeutics (HALO)	$8.3B
Roivant Sciences (ROIV)	$8B